Abstract
The conjugation of lactoferrin and lactoferricin to the dendrimer significantly increased the gene expression in the tumor while decreasing the non-specific gene expression in the liver. Consequently, the intravenous administration of the targeted dendriplexes encoding TNFα led to the complete suppression of 60% of A431 tumors and up to 50% of B16-F10 tumors over one month. The treatment was well tolerated by the animals. These results suggest that these novel lactoferrin- and lactoferricin-bearing dendrimers are promising gene delivery systems for cancer therapy.
| Language | English |
|---|---|
| Pages | 1445-1454 |
| Number of pages | 10 |
| Journal | Nanomedicine: Nanotechnology, Biology and Medicine |
| Volume | 11 |
| Early online date | 28 Apr 2015 |
| DOIs | |
| Publication status | Published - Aug 2015 |
Fingerprint
Keywords
- cancer therapy
- gene delivery
- endrimer
- lactoferricin
- lactoferrin
Cite this
}
Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes. / Lim, Li Ying; Koh, Pei Yin; Somani, Sukrut; Al Robaian, Majed; Karim, Reatul; Yean, Yi Lyn; Mitchell, Jennifer; Tate, Rothwelle J.; Edrada-Ebel, RuAngelie; Blatchford, David R.; Mullin, Margaret; Dufès, Christine.
In: Nanomedicine: Nanotechnology, Biology and Medicine, Vol. 11, 08.2015, p. 1445-1454.Research output: Contribution to journal › Article
TY - JOUR
T1 - Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes
AU - Lim, Li Ying
AU - Koh, Pei Yin
AU - Somani, Sukrut
AU - Al Robaian, Majed
AU - Karim, Reatul
AU - Yean, Yi Lyn
AU - Mitchell, Jennifer
AU - Tate, Rothwelle J.
AU - Edrada-Ebel, RuAngelie
AU - Blatchford, David R.
AU - Mullin, Margaret
AU - Dufès, Christine
PY - 2015/8
Y1 - 2015/8
N2 - The possibility of using gene therapy for the treatment of cancer is limited by the lack of safe, intravenously administered delivery systems able to selectively deliver therapeutic genes to tumors. In this study, we investigated if the conjugation of the polypropylenimine dendrimer to lactoferrin and lactoferricin, whose receptors are overexpressed on cancer cells, could result in a selective gene delivery to tumors and a subsequently enhanced therapeutic efficacy. The conjugation of lactoferrin and lactoferricin to the dendrimer significantly increased the gene expression in the tumor while decreasing the non-specific gene expression in the liver. Consequently, the intravenous administration of the targeted dendriplexes encoding TNFα led to the complete suppression of 60% of A431 tumors and up to 50% of B16-F10 tumors over one month. The treatment was well tolerated by the animals. These results suggest that these novel lactoferrin- and lactoferricin-bearing dendrimers are promising gene delivery systems for cancer therapy.
AB - The possibility of using gene therapy for the treatment of cancer is limited by the lack of safe, intravenously administered delivery systems able to selectively deliver therapeutic genes to tumors. In this study, we investigated if the conjugation of the polypropylenimine dendrimer to lactoferrin and lactoferricin, whose receptors are overexpressed on cancer cells, could result in a selective gene delivery to tumors and a subsequently enhanced therapeutic efficacy. The conjugation of lactoferrin and lactoferricin to the dendrimer significantly increased the gene expression in the tumor while decreasing the non-specific gene expression in the liver. Consequently, the intravenous administration of the targeted dendriplexes encoding TNFα led to the complete suppression of 60% of A431 tumors and up to 50% of B16-F10 tumors over one month. The treatment was well tolerated by the animals. These results suggest that these novel lactoferrin- and lactoferricin-bearing dendrimers are promising gene delivery systems for cancer therapy.
KW - cancer therapy
KW - gene delivery
KW - endrimer
KW - lactoferricin
KW - lactoferrin
UR - http://www.nanomedjournal.com/
U2 - 10.1016/j.nano.2015.04.006
DO - 10.1016/j.nano.2015.04.006
M3 - Article
VL - 11
SP - 1445
EP - 1454
JO - Nanomedicine: Nanotechnology, Biology and Medicine
T2 - Nanomedicine: Nanotechnology, Biology and Medicine
JF - Nanomedicine: Nanotechnology, Biology and Medicine
SN - 1549-9634
ER -